期刊文献+

宫颈癌不同临床分期放疗抗拒与缺氧诱导血管新生的关系 被引量:5

The relationship between resistance after radiotherapy and hypoxia-induced angiogenesis at different clinical stages of cervical squamous cell carcinoma
下载PDF
导出
摘要 目的探讨不同临床分期的宫颈癌放疗抗拒与肿瘤缺氧诱导血管新生的关系及意义。方法选取91例不同临床分期的宫颈鳞癌放疗患者,采用免疫组织化学SP法检测乏氧细胞诱导因子(HIF-1α)、血管内皮生长因子(VEGF),并用CD105标记新生微血管密度(MVD)。结果随着临床分期的加重,肿瘤的放疗抗拒增大。VEGF、HIF-1α在宫颈鳞癌Ⅱb~Ⅳ期放疗后抗拒的阳性表达率升高,差异有统计学意义(P<0.05)。HIF-1α、VEGF与MVD在不同临床分期之间存在正相关,且随临床分期的加重,MVD的计数逐渐增加,差异有统计学意义(P<0.05)。结论随着宫颈鳞癌的临床分期加重,肿瘤的放疗抗拒加重,HIF-1α、VEGF、MVD的表达与之相关,可作为宫颈鳞癌放疗后判断预后的可靠依据。 Objective To investigate the relationship and significance between radiotherapy resistance and angiogenesis induced by hypoxia in patients with cervical squamous cell carcinoma (SCC) at different clinical stages. Methods 91 patients with cervical SCC at different clinical stages who were treated by radiotherapy were enrolled in the investigation. The immunohistrochemical assay was used to detect the expressions of HIF-1α, VEGF,COX-2, and microvessel density (MVD) was marked by CDl05. Results The radiotherapy resistance of cervical SCC was increased with the aggravation of clinical stages. The positive expression rates of VEGF, HIF-1α at Ⅱb~Ⅳ stages after radiotherapy were significantly increased ( P 〈 0.05 ). There was a positive correlation between HIF-1α, VEGF and MVD at different clinical stages, furthermore, the count of MVD was gradually increased with the aggravation of clinical stages, and there was a significant difference ( P 〈 0. 05 ). Conclusion The radiotherapy resistance of cervical SCC is increased with the aggravation of clinical stages. There is a positive correlation between HIF-1α, VEGF, MVD and different clinical stages, which can be used as the reliable evidence for evaluating the prognosis of patients with cervical SCC after radiotherapy.
出处 《河北医药》 CAS 2011年第16期2416-2418,共3页 Hebei Medical Journal
关键词 肿瘤血管新生 HIF—1α VEGF 放疗抗拒 tumor angiogenesis HIF-1α VEGF radiotherapy resistance
  • 相关文献

参考文献9

  • 1余子豪,殷巍伯,徐国镇主编.肿瘤放射治疗学.第4版.北京:中国协和医科大学出版社,2008.232-320.
  • 2Wong C,Wellman TL, Lounsbury KM. VEGF and HIF-lctexpression are increased in advanced stages of epithelial ovarian cancer. Gynecologic On- cology,2003,91:513-517.
  • 3Habeck H, Odemthal J, Walderieh B, et al. Analysis of a zebrafish VEGF receptor mutant reveals specific disruption of angiogenesis. Curr Biol, 2002, 12:1405-1412.
  • 4Tseng PL,Tai MH, Huang CC, et al. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. Journal of Surgical Oncology,2008,98 : 349-57.
  • 5Wenger RH, Gassmann M. Oxygen (es) and the hypoxia-inducible factor- 1. Biological Chemistry, 1997,378:609-616.
  • 6Nakayama K, Kanzaki A, Hata K, et al. Hypoxia-inducible factor 1 alpha ( HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett, 2002,176:215-223.
  • 7Bimer P, Schindl M, Obermair A, et al. Expression of hypoxia-inducible factor-1α in epithelial ovarian tumors : its impact on prognosis and on response to chemotherapy. Clin Cancer Res,2001,7:1661-1668.
  • 8李素文,朱宝申,郝惠英,黄卫平.VEGF和MMP-9在宫颈癌组织中的表达[J].河北医药,2009,31(17):2290-2291. 被引量:2
  • 9梁华茂.宫颈癌的病因学研究进展[J].中国全科医学,2010,13(29):3239-3241. 被引量:21

二级参考文献28

  • 1邵彬,聂青和.基质金属蛋白酶组织抑制剂(TIMPs)的基础及临床研究现状[J].实用肝脏病杂志,2005,8(3):182-186. 被引量:29
  • 2石新兰,黎家华,胡余昌,王飞,姚佳红.p65及MMP-2、MMP-9、TIMP-2、TIMP-1在宫颈鳞癌的表达状态[J].肿瘤,2006,26(2):199-202. 被引量:3
  • 3Erik Malmqvist, Gert Helgesson, Johannes Lehtinen, et al. The ethics of implementing human papillomavirus vaccination in developed countries (J ]. Medicine, Health Care, and Philosophy, Published online, 2010.
  • 4Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases [ J ]. Public Health Genomics, 2009, 12:291-307.
  • 5Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship [ J ]. B JOG : An International Journal of Obstetrics and Gynaecology, 2002, 109: 96-98.
  • 6Castellsague X, De Sanjose S, Aguado T, et al. HPV and Cervical Cancer in the World. 2007 Report. WHO/ICO information centre on HPV and cervical cancer (HPV Information Centre) [ R]. Vaccine, 2007, 25 (Suppl3) .
  • 7Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis [J]. Lancet, 2005, 366:991-998.
  • 8Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high - grade cervical lesions and cervical cancer: a meta - analysis [J]. BrJCancer, 2003, 89:101-105.
  • 9Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high - grade cervical lesions : a meta - analysis update [ J ]. Int J Cancer, 2007, 121 : 621 - 632.
  • 10Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide [ J ]. J Pathol, 1999, 189: 12-19.

共引文献21

同被引文献35

  • 1王中华,缪小平,谭文,张湘茹,徐兵河,林东昕.XRCC1单核苷酸多态与晚期非小细胞肺癌对铂类药物化疗敏感性的相关性[J].癌症,2004,23(8):865-868. 被引量:56
  • 2杨斌,瞿全新.HIF-1α与TRAIL-DR4在宫颈癌组织中的表达及与放疗敏感性的研究[J].现代妇产科进展,2007,16(1):21-24. 被引量:5
  • 3袁响林,于世英,庄亮,谢涛,杨彬,董兰兰,熊华.RNA干扰HIF-1α增强宫颈癌BALB/c小鼠移植瘤放射敏感性[J].中国癌症杂志,2007,17(4):303-306. 被引量:3
  • 4Przybylowska-Sygut K, Stanczyk M, Kusinska R, et al. Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCCI gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer[J]. Clin Breast Cancer, 2013,13(1):61-68. doi: lO.lO16/j.clbc.2012.09.019.
  • 5Cheng XD, Lu WG, Ye F, et al. The association of XRCC1 gene sin- gle nucleotide polymorphisms with response to neoadjuvant chemo- therapy in locally advanced cervical carcinoma[J]. J EXP Clin Can- cer Res, 2009,28(1):91. doi: 10.1186/1756-9966-28-91.
  • 6P6ez D, Salazar J, Par6 L, et al. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: poly- morphisms in thymidylate synthase, epidermal growth factor recep- tor, GSTP1, and DNA repair genes[J]. Int J Radiat Oncol Biol Phys, 2011,81(5):1319-1327. doi: 10.1016/j.ijrobp.2011.01.025.
  • 7Meijer TW,Kaanders JH,Span PN,et al.Targeting hypoxia,HIF-1,and tumor glucose metabolism to improve radiotherapyefficacy[J].Clin Cancer Res,2012,18(20):5585-5594.
  • 8Adams JM,Difazio LT,Rolandelli RH,et al.HIF-1α key mediatorin hypoxia[J].Acta Physiol Hung,2009,96(1):19-28.
  • 9Brown JM.Tumor hypoxia in cancer therapy [J].MethodsEnzymol,2007,435:297-321.
  • 10Zhang ZG,Zhang QN,Wang XH,et al.Hypoxia-inducible factor 1alpha(HIF-1α)as a prognostic indicator in patients with gastrictumors:A meta-analysis[J].Asian Pac J Cancer Prev,2012,14(7):4195-4198.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部